Furosemide
(Synonyms: 呋塞米) 目录号 : GC12970
A loop diuretic and an inhibitor of NKCC1 and NKCC2
Cas No.:54-31-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Furosemide is an inhibitor of Na+/2Cl-/K+ cotransporter [1].
The Na-K-Cl cotransporter (NKCC) is a protein that acts as an active transporter helping sodium, potassium, and chloride into and out of cells. NKCC1 has important functions in organs that secrete fluids. NKCC2 exists in the kidney and serves to extract sodium, potassium, and chloride from the urine [2].
Furosemide is an antagonist of Na+/2Cl-/K+ cotransporter. In adult brain tissue, furosemide blocked the epileptiform activity through inhibiting cell swelling, which was concomitant with its inhibition of activity-driven changes of the extracellular space (ECS) [1]. Furosemide inhibited the production and release of cytokines IL-6, IL-8, and TNF-ɑ from peripheral mononuclear cells and exhibited an anti-inflammatory effect [3].
In patients with liver cirrhosis, furosemide inhibited the natriuretic effect and increased the levels of atrial natriuretic factor (ANF) and circulating endothelin. In neonates, furosemide significantly increased the urinary excretion of aldosterone and endothelin-1 [3].
References:
[1]. Hochman DW. The extracellular space and epileptic activity in the adult brain: explaining the antiepileptic effects of furosemide and bumetanide. Epilepsia, 2012, 53 Suppl 1: 18-25.
[2]. Chen H, Sun D. The role of Na-K-Cl co-transporter in cerebral ischemia. Neurol Res, 2005, 27(3): 280-286.
[3]. Prandota J. Furosemide: progress in understanding its diuretic, anti-inflammatory, and bronchodilating mechanism of action, and use in the treatment of respiratory tract diseases. Am J Ther, 2002, 9(4): 317-328.
| Cas No. | 54-31-9 | SDF | |
| 别名 | 呋塞米 | ||
| 化学名 | 4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid | ||
| Canonical SMILES | C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl | ||
| 分子式 | C12H11ClN2O5S | 分子量 | 330.74 |
| 溶解度 | ≥ 14.9mg/mL in DMSO | 储存条件 | 4°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.0235 mL | 15.1176 mL | 30.2352 mL |
| 5 mM | 0.6047 mL | 3.0235 mL | 6.047 mL |
| 10 mM | 0.3024 mL | 1.5118 mL | 3.0235 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。